individual-specific neoantigen peptide vaccine

The individual-specific neoantigen peptide vaccine is a personalized cancer immunotherapy designed to elicit a T-cell response against unique mutations (neoantigens) found within a patient's tumor. The process involves sequencing the patient's tumor and healthy tissue to identify somatic mutations, predicting which of these mutations will result in peptides that can be presented by the patient's HLA molecules, and then synthesizing these specific peptides for administration. This approach aims to overcome the limitations of traditional cancer vaccines that target shared antigens, which may be subject to central tolerance. In the context of the trial at Tianjin Beichen Hospital (ChiCTR-IIR-17010557), the vaccine is being evaluated for safety and feasibility in patients with advanced solid tumors.

Other names

individual-specific mutant peptide vaccinepersonalized neoantigen peptide vaccine